Inclisiran: a new generation of lipid-lowering siRNA therapeutic

Frontiers in Pharmacology

Pharmacology

Hong Wang¹  Liu Yang¹  Bin Li¹  Lang Hong¹  Fan Liu²  Yanzhen Zhang³  Jiamei Li⁴  Huaigang Chen⁵  Mengyin Zhang⁶ 

[1]Department of Cardiology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China

[2]Department of Hematology Jiangxi Hospital of Traditional Chinese Medicine, Nanchang, China

[3]Department of Rheumatology, Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital, Beijing, China

[4]Laboratory Department, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China

[5]Medical College of Nanchang University, Nanchang, China

[6]Department of Cardiology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China

[7]Pharmacy Department, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China

关键词: lipid-lowering therapies;    cardiovascular risk;    PCSK9;    Inclisiran;    siRNA;   

DOI  :  10.3389/fphar.2023.1260921

 received in 2023-07-18, accepted in 2023-10-03,  发布年份 2023

来源: Frontiers

【 摘 要 】

Atherosclerotic heart disease (AHD) is a major cause of morbidity and mortality worldwide. Lowering low-density lipoprotein cholesterol (LDL-C) levels is a key strategy to prevent and treat AHD. Inclisiran is a novel siRNA drug that targets proprotein convertase subtilisin/kexin type 9 (PCSK9) gene expression and reduces LDL-C levels with only two or three injections per year. This review summarizes the mechanism, efficacy, safety, and applications of Inclisiran in various populations and settings, based on recent literature. It also compares Inclisiran with other lipid-lowering drugs, especially other PCSK9 inhibitors. We conclude that Inclisiran is a promising lipid-lowering agent that can provide convenience and effectiveness for patients with high cardiovascular risk. However, some challenges and limitations remain for Inclisiran, such as its long-term safety and efficacy, its cost-effectiveness and accessibility, and its interactions and synergies with other drugs. These issues need further investigation and evaluation in future studies.

【 授权许可】

Unknown   
Copyright © 2023 Zhang, Chen, Hong, Wang, Li, Zhang, Li, Yang and Liu.